Dr. Druker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 Sw Sam Jackson Park Rd, L952
Portland, OR 97239Phone+1 503-494-5596Fax+1 503-494-3688
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1987
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1981 - 1984
- University of California San Diego School of MedicineClass of 1981
Certifications & Licensure
- OR State Medical License 1993 - 2025
- WA State Medical License 2022 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2007-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Portland Monthly Magazine Castle Connolly, 2011
- Join now to see all
Clinical Trials
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Publications & Presentations
PubMed
- 80 citationsOcular side-effects associated with imatinib mesylate (Gleevec).Frederick W. Fraunfelder, Jonathan Solomon, Brian J. Druker, Bita Esmaeli, Jennifer M. Kuyl
Journal of Ocular Pharmacology and Therapeutics. 2003-08-01 - 236 citationsProteogenomic characterization of pancreatic ductal adenocarcinomaLiwei Cao, Chen Huang, Daniel Cui Zhou, Yingwei Hu, T. Mamie Lih
Cell. 2021-09-16 - 260 citationsProteogenomic Characterization of Endometrial Carcinoma.Yongchao Dou, Emily Kawaler, Daniel Cui Zhou, Marina A. Gritsenko, Chen Huang
Cell. 2020-02-20
Journal Articles
- CRISPR-Cas9–Mediated Saturated Mutagenesis Screen Predicts Clinical Drug Resistance with Improved AccuracyRichard D Press, Brian J Druker, Michael R Green, Proceedings of the National Academy of Sciences
Press Mentions
- OHSU Experts Elected to the National Academy of Medicine, One of the Highest Honors in the Fields of Health, MedicineOctober 21st, 2024
- How Artificial Intelligence Is Aiding in Cancer ResearchSeptember 15th, 2024
- Internationally Renowned OHSU Cancer Biologist Elected to the National Academy of SciencesMay 2nd, 2023
- Join now to see all
Grant Support
- Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute2011–2012
- Senior LeadershipNational Cancer Institute2011
- Protocol Specific Research SupportNational Cancer Institute2011
- Protocol Review &Monitoring SystemNational Cancer Institute2011
- Proteomics Shared ResourceNational Cancer Institute2011
- Program Planning And EvaluationNational Cancer Institute2011
- Program LeadershipNational Cancer Institute2011
- Histapathology &Cancer Genotyping Shared ResourceNational Cancer Institute2011
- Flow Cytometry Shared ResourceNational Cancer Institute2011
- Developmental FundsNational Cancer Institute2011
- Data Safety Monitoring SystemsNational Cancer Institute2011
- Clinical Research Management Shared ResourceNational Cancer Institute2011
- Bioanalytical/Pharacokinetic Shared ResourceNational Cancer Institute2011
- AdministrationNational Cancer Institute2011
- Ohsu Knight Cancer InstituteNational Cancer Institute2009–2011
- Ohsu Knight Cancer Institute- Community Health Educator SupplementNational Cancer Institute2010
- Ohsu Knight Cancer Institute - Rapid SupplementNational Cancer Institute2010
- Accelerating Target Identification And Validation In Leukemia: Integrating Sirna-National Cancer Institute2009–2010
- Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute1995–2009
- Ohsu Cancer InstituteNational Cancer Institute2007–2008
- Cancer And KinasesNational Cancer Institute2005
- CBL Function In Cellular Signaling And TransformationNational Cancer Institute1999–2003
- Tyrosine Kinase Inhibitors As Antineoplastic AgentsNational Cancer Institute1999–2001
- Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1993–1994
- Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1990–1992
- Mutagenesis Of Polyoma Middle-T AntigenNational Cancer Institute1986
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: